- Sites are being initiated for the Company’s phase II clinical trial of Oral Anti-TNF, or OPRX-106, for the treatment of Ulcerative Colitis, with patient enrollment expected to commence before year-end.
Catalyst
Slingshot members are tracking this event:
Enrollment Expected to Commence Soon in Phase 2 Trial Evaluating Protalix' (PLX) OPRX-106 in Ulcerative Colitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PLX |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 30, 2016
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=2226448
Related Projects
- Potential for Protalix' (PLX) OPRX-106 in Ulcerative Colitis, and What to Expect from Phase 2 Data PLX Execute By: Mar 31, 2017
Related Keywords
Prx-106, Ulcerative Colitis
